Open an account

Xenon Pharmaceuticals

XENE · NASDAQ

$36.27+$1.19 (+3.39%)TodayMarket closed ·
Prev close $35.08

About XENE

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 358 full-time employees. The company went IPO on 2014-10-17. The firm is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The firm is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.

Employees
364
Headquarters
Vancouver, British Columbia
Listed
Oct 17, 2014
Sector
Health Care
Industry
Biotechnology
Website
xenon-pharma.com

XENE key statistics

Market cap
6.20B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.17M
Volume
989.69K
Open price
$35.14
High today
$36.65
Low today
$35.10
52 Week high
$72.66
52 Week low
$33.38

Xenon Pharmaceuticals (XENE) at a glance

As of Oct 20, 2026, Xenon Pharmaceuticals (XENE) shares are priced at $36.27, giving the company a market cap of 6.20B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $35.10 and $36.65. The current price is 3.3% above the day's low and 1.0% below its high.

Volume so far is 989.69K shares, below the average of 2.17M shares a day.

Over the past year Xenon Pharmaceuticals has ranged from $33.38 to $72.66, and now sits 7% of the way up that range.

Xenon Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$1.11 per share against an estimate of -$1.16.

The average analyst price target is $75.48, 108.1% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

90%of 10 analyst ratings say Buy
  • Buy90.0%
  • Hold10.0%
  • Sell0.0%
Price target · 20 analystsAvg $75.48
Low
$46.46
Now
$36.27
High
$94.50

XENE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 4.5% on average.

  1. Q3 FY24: reported -$0.81 per share against an estimate of -$0.8316
  2. Q4 FY24: reported -$0.84 per share against an estimate of -$0.8779
  3. Q1 FY25: reported -$0.83 per share against an estimate of -$0.93
  4. Q2 FY25: reported -$1.07 per share against an estimate of -$1.01
  5. Q3 FY25: reported -$1.15 per share against an estimate of -$1.17
  6. Q4 FY25: reported -$1.31 per share against an estimate of -$1.22
  7. Q1 FY26: reported -$1.17 per share against an estimate of -$1.21
  8. Q2 FY26: reported -$1.11 per share against an estimate of -$1.16

XENE news

  • Press releaseBusiness Wire

    XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

  • Press releasePRNewswire

    Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)

  • Press releaseGlobe Newswire

    Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

  • Avi Kapoor

    Dow Falls Over 200 Points; Xenon Pharmaceuticals Shares Plunge

  • Vandana Singh

    Xenon Stock Reaction Is Overblown: Analyst

  • Avi Kapoor

    US Stocks Mixed; Industrial Production Unchanged In August

  • Market-Moving News for September 18th

  • Tanya Rawat

    Xenon Pharmaceuticals (XENE) Shares Fall 25% After Hours: Here's Why

Similar companies

Companies in the same industry as Xenon Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.